NAMIBIA MEDICINES REGULATORY COUNCIL

MINISTRY OF HEALTH AND SOCIAL SERVICES

APPLICATION FOR REGISTRATION OF A VETERINARY MEDICINE

APPLICATION NUMBER

PART 1 ADMINISTRATIVE INFORMATION

PART 1A ADMINISTRATIVE PARTICULARS

(a) Particulars of the Applicant/Prospective holder of the certificate of registration (PHCR)

Name: .....

Business address: .....

Postal address: .....

Telephone No: .....

Fax No: .....

E-Mail address: .....

Site/Applicant Master File Number: .....

Person responsible/ authorised to communicate with Council:

Name: .....

Business address: - .....

.....

Telephone no: .....

Fax No.: .....

E-mail: .....

(Attach a letter of authorisation signed by the person responsible for the overall management and control of the business)

(b) Particulars of the veterinary medicine

Proprietary name: .....

Pharmacological Classification: .....

Dosage form: .....

Approved name:

Strength(s) per dosage unit: .....

Descriptive name of veterinary biological: .....

Route of administration: .....

Country of origin (country in which the original development was carried out): .....

Indicate with an X in the appropriate block if the application is for a

☐New product with new active ☐new product with existing active
☐Amendment to existing product - Registration no. ☐☐☐☐☐☐☐☐
☐Parallel product ☐daughter product ☐multi-source product ☐veterinary biological

Manufacturer(s): .....

Physical address of site(s): .....

Site Master File reference number(s): .....

Packer(s): .....

Physical address of site(s): .....

Site Master File reference number(s): .....

Final product release control (FPRC) (s): .....

Physical address of site(s): .....

Site Master File reference number(s): .....

Final product release responsibility (FPRR) (s): .....

Physical address of site(s): .....

Site/Applicant Master File number(s): .....

The undersigned hereby declares that all the information herein, and in the PARTS hereto, are correct and true and are relevant to this particular medicine.

.....	.....
Signature of responsible person	Signature of pharmacist (if responsible person is not a pharmacist)
.....	.....
Name in block letters	Date of application
.....	.....
Designation	Date of current amendment (Post-registration only)

(c) Amendment history (Post-registration only)		
Date of letter of amendment application	Summarised details of amendment	Date of Council response

PART 1B TABLE OF CONTENT

A comprehensive table of content of the dossier, including the SUB-PARTS of each PART, must be provided.

PART 1C LABELLING

(a) Veterinary Medicine Scientific Package insert

The under-mentioned information with regard to this medicine must appear on the package insert. The information must be presented in the format stipulated, provided that the Council may authorise any deviation from such information or such format (refer to Regulation 15(2)).

1. The words "**Veterinary Medicine**"
2. Scheduling status
3. Proprietary name and dosage form
4. Composition
5. Pharmacological classification
6. Pharmacological action (Pharmacokinetics, pharmodynamics and summary of clinical studies where applicable)
7. Indications per species
8. Contra-indications
9. Warnings or withdrawal period in the case of food-producing animals
   Safety in pregnancy and lactation
10. Dosage and directions for use including per age and species dosage
11. Side effects and special precautions for use per species.
12. Interactions
13. Known signs of overdosage and particulars of its treatment per species
14. Identification
15. Presentation
16. Storage instructions
17. Registration number (or reference number)
18. Name and business address of the holder of the certificate of registration
19. Date of notification of approval of this scientific package insert

(b) Label

A facsimile of the immediate container label and, if applicable, the outer label must be included here.
This must conform to Regulation 14.

PART 1D FOREIGN REGISTRATION

(a) A list of countries in which an application has been lodged and the status of these applications must be furnished, detailing approvals, deferrals, withdrawals and rejections.

(b) If the medicine has been registered by the regulatory authorities with which Council aligns itself, i.e. RSA (MCC), USA (FDA), European Union (EMEA), UK (MHRA), Sweden (MPA), Canada (Health Canada), Australia (TGA), and Japan (MWH), include -

- a copy of the certificate of registration,
- the conditions of registration and
- the approved package insert (data sheet) translated into English where relevant.

(c) Details of any negative decision by any regulatory authority reflected in PART 1D(b) must be provided.

PART 2 BASIS FOR REGISTRATION AND OVERVIEW OF APPLICATION

PART 2A BIOEQUIVALENCE AND BIOAVAILABILTY

(a) State the purpose of the study

(i) As comparison of formulation to be marketed versus formulation used in clinical trials, or

(ii) As proof of efficacy for a multi-source application, or

(iii) As proof of efficacy of new formulation (formulation change)

(b) Reference product used

(i) Clinical trial formulation

(ii) Innovator product

(iii) Current formulation (for change of formulation)

The following must be indicated:

	Reference product	Formulation applied for
Name of product		
Batch no.		
Holder of certificate of registration		
Country where purchased		
Assay results		
Source of Active Pharmaceutical Ingredient		

(c) Method used

Describe the method in full, e.g. bioavailability, dissolution, etc.

(d) Validation

Validation data for all quantitative assay methods must be included.

(e) Studies

Include protocol , final report , assay validation report , pharmacokinetic report (including individual animal data) and statistical report.

(f) Discussion and Conclusion

Attach documents (where applicable).

Partial or total exemption from the requirements of this PART may be applicable if efficacy and safety are intended to be established by clinical data (or for other reasons determined by Council), provided that clinical trials have been conducted with the same formulation as the one being applied for.

PART 2B SUMMARY BASIS FOR REGISTRATION APPLICATION FOR A VETERINARY MEDICINE (SBRAV)

The following is a summary of the core data in support of the clinical safety and efficacy.

In cases concerning well-known active pharmaceutical ingredients, or if Non-clinical and Clinical Overviews are submitted , the Council may grant exemption from the submission of an SBRAV.

PART 2 C PHARMACEUTICAL EXPERT REPORT (PER)

The following is an independent, objective and encompassing report in light of current scientific knowledge addressing all the quality aspects of the product.

In cases concerning well-known active pharmaceutical ingredients, the Council may grant exemption from the submission of the above report.

PART 2D PRE-CLINICAL EXPERT REPORT (PCER)

The following is an independent, objective and encompassing report in light of current scientific knowledge addressing all the non-clinical aspects of the development of the product and of the relevant aspects referred to in the package insert.

In cases concerning well-known active pharmaceutical ingredients, or if an SBRAV is submitted, the Council may grant exemption from the submission of the above report.

PART 2E CLINICAL EXPERT REPORT (CER)

The following is an independent, objective and encompassing report in light of current scientific knowledge on all the clinical aspects of the development of the product and of the relevant aspects referred to in the package insert.

In cases concerning well-known active pharmaceutical ingredients, or if an SBRAV is submitted, the Council may grant exemption from the submission of the above report.

PART 3 QUALITY CONTROL

PART 3A(i) ACTIVE PHARMACEUTICAL INGREDIENT (API) VETERINARY PHARMACEUTICALS

(a) The name(s), structural formulae, empirical formulae, molecular mass, solubility and storage requirements are tabulated as follows:

International Non-proprietary Name (INN) or approved name or chemical name/description	Structural formula, empirical formula, molecular mass	Solubility	Storage requirements	Retest period

(b) The API is obtained from the following sources (names and business addresses of the manufacturers):

(c) Active Pharmaceutical Ingredient File (APIF) or Drug Master File (DMF - open part) or certificate of suitability (CEP) must be included

PART 3A(ii) VETERINARY BIOLOGICALS

PRIMARY PRODUCTION LOT/BATCH

1. Description of the preparation and production of the primary production lot.

(a) Name and address of the manufacturing facility in which production of the primary production lot takes place.

(b) Master seed identification, description and control.

(c) The complete description of the preparation and manufacturing process of the primary production or bulk lot, the tests carried out on the product and the stages at which such tests are carried out to confirm the integrity of the product must be submitted.

2. Specifications of ingredients used in the primary production lot.

The following are the specifications that apply to the ingredients used in the primary production or bulk lot of a veterinary biological medicine, including the titles of the tests and the limits and criteria of acceptance of each parameter contained in the specification. (Where the test mentioned corresponds to a recognised pharmacopoeia, the source must be mentioned):

3. Tests carried out on ingredients in the primary production lot and details of the laboratories involved

The following is a complete description of the tests carried out on all the ingredients used in the primary production or bulk lot, specifying the name and address of the laboratory(ies) in which such tests are carried out.

PART 3 B FORMULATION

(a) Veterinary medicine: final dosage form
Veterinary biological: final filling lot/batch

Below is a schedule of the names and quantities of each active and inactive pharmaceutical ingredient contained in a dosage unit. If no dosage unit exists, another suitable unit of mass or volume of the veterinary medicine may be used as long as the relevant particulars regarding the active pharmaceutical ingredients correspond in the package insert and on the label.

The purpose(s) of each inactive ingredient in the formulation must be specified, including that of those ingredients used during manufacturing but which are not present in the final product.

Approved name	Quantity per dosage unit	Active or inactive	Purpose of inactive

(b) Veterinary medicine: diluent (if applicable)
Veterinary biological: final filling lot reconstituting liquid/diluent

Below is a schedule of the names and quantities of each pharmaceutical ingredient contained in a dosage unit.

The purpose of each ingredient must be specified, including those used but which are not present.

Approved name	Quantity	Purpose

PART 3C SPECIFICATIONS AND CONTROL PROCEDURES FOR PHARMACEUTICAL INGREDIENTS

(a) Pharmacopoeial ingredients

Pharmaceutical Ingredient		Pharmacopoeial reference*	Any additional specifications (e.g. particle size)	Any additional control procedures
Active				
Inactive				

*The latest edition of the pharmacopoeia is implied, unless otherwise specified and justified.

(b) Non-pharmacopoeial ingredients

Pharmaceutical Ingredient		Title of Specification	Limits	Control procedures
Active				
Inactive				

(c) Laboratory

The identification and assay of the API and identification of the inactive pharmaceutical ingredients (IPIs) are tested by the following laboratory (name and business address of the laboratory).

PART 3 D CONTAINERS AND PACKAGING MATERIALS

(a) Immediate container

The following is a description of the immediate container(s), the nature of the material, closure, pack sizes, specifications and the control procedures performed by the manufacturer/packer of the final product. The tests performed by the supplier are indicated.

(b) Outer container

The following is a brief description of the outer container.

(c) Bulk container

The following is a brief description of the bulk container.

(d) Applicator and administration sets

The following is a description of the applicator and administration sets (if applicable), the type of material and dimensions including sketches.

PART 3E MANUFACTURING PROCEDURES

Veterinary medicine: **manufacturing procedures of final product**
Veterinary biological: **final filling lot and diluent**

The comprehensive procedure of manufacture, detailing the

- various stages of manufacture
- packaging procedure,
- batch manufacturing formulations(s) and batch size(s),
- in-process control procedures and the frequency with which they are carried out during the manufacturing and packaging process, and the

- names and addresses of the different manufacturing and packaging facilities/sites where the various stages of manufacturing and packaging are carried out if more than one site is involved,

are as follows:

PART 3F FINAL PRODUCT SPECIFICATIONS AND CONTROL

Veterinary medicine: **final product**
Veterinary biological: **final filling lot and diluent**

(a) Specifications (titles and limits)

List the specifications (titles and limits) for the following, if applicable:

(i) In-process control
(ii) Final product control
(iii) Stability testing
(iv) Reconstituted/diluted final product

Title of Specification	Limits

(b) Control

	Final release criteria
FPRC	
FPRR	

(c) Control procedures and validation

The control procedures for the specifications and validation of the analytical assay methods in section (a) and a final product certificate of analysis are included.

PART 3G STABILITY DATA FOR THE FINISHED PRODUCT

(a) Stability programme

Describe the stability programme to be followed and include the following:

(i) Conditions (temperature, humidity)
(ii) Time points of determination, e.g. 0, 3, 6, 9 months, etc.

(b) Discussion and motivation of shelf-life for each type of container

(c) Stability data

(d) Stability test control procedures and validation if different to those of the final product.

PART 3H PHARMACEUTICAL DEVELOPMENT

The following is a description of the pharmaceutical development of the product addressing the choice of formulation, ingredients and containers, overages, manufacture, stability and tests carried out during the development clearly identifying the clinical trial formulations.

PART 3I EXPERTISE AND PREMISES USED FOR THE MANUFACTURE OF VETERINARY BIOLOGICALS

(a) Details relating to the premises where the primary production is undertaken and the staff involved in the production and testing of veterinary biologicals

(b) Name and address of the facility where the final filling lot is stored if imported and/or different to that given in (a).

PART 4 PRE-CLINICAL STUDIES

(a) Pre-clinical Expert Report

(b) The following are results obtained and conclusions drawn from tests performed pre-clinically to demonstrate all aspects of the toxicity of the medicine and to prove the safety of its use, with special reference to -

(i) acute toxicity
(ii) subacute toxicity studies
(iii) chronic toxicity studies
(iv) reproduction toxicity and teratogenicity studies
(v) carcinogenicity studies
(vi) mutagenicity studies, or
(vii) environmental impact studies
(viii) pharmacokinetics studies
(ix) neurological studies
(x) other tests to substantiate the safety of the veterinary medicine

(c) The following are results obtained of and conclusions drawn from tests performed pre-clinically to demonstrate all aspects of the efficacy of the veterinary medicine, with special reference to:

(i) The methods and experimental results of and the conclusions drawn from tests performed pre-clinically with reference to the efficacy of the veterinary medicine ;
(ii) the relationship between the tests performed and the purpose for which the veterinary medicine is or will be used, or for which it will be propagated, and
(iii) the dosage and method of administration of the veterinary medicine:

In cases concerning well-known active pharmaceutical ingredients, the Council may grant exemption from the submission of some or all of the above information.

PART 5 CLINICAL STUDIES

(a) Clinical Expert Report

(b) The field trials performed on target species with regard to the safety of the use of the veterinary medicine, with special reference to the particular dosage, routes of administration used and the side-effects observed per species, are as follows:

(c) The particulars of clinical or field trials conducted to establish the efficacy of the use of the veterinary medicine, are as follows:

(d) Experimental details and results of the studies performed to establish the correlation between the applicable blood and other suitable physiological concentrations and the pharmacological action claimed for the veterinary medicine, are as follows:

(e) Veterinary medicines for food-producing animals: Residue depletion studies and recommended withdrawal periods, are as follows:

(f) Periodic Safety Update report for medicines for veterinary use

In cases concerning well-known active pharmaceutical ingredients, the Council may grant exemption from the submission of some or all of the above information.